Hyaluronan-modified nanoceria for dry eye disease treatment

Fang Wu; Zeen Lv; Yingzheng Mao; Tianji Feng; Jiayan Zhu; Jiaying Deng; Ke Yao; Haijie Han

doi:10.1016/j.jcis.2024.12.174

Hyaluronan-modified nanoceria for dry eye disease treatment

J Colloid Interface Sci. 2024 Dec 25;683(Pt 2):215-225. doi: 10.1016/j.jcis.2024.12.174. Online ahead of print.

Authors

Fang Wu¹, Zeen Lv¹, Yingzheng Mao¹, Tianji Feng¹, Jiayan Zhu¹, Jiaying Deng¹, Ke Yao², Haijie Han³

Affiliations

¹ Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou 310009, China.
² Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou 310009, China. Electronic address: xlren@zju.edu.cn.
³ Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou 310009, China. Electronic address: hanhj90@zju.edu.cn.

PMID: 39733537
DOI: 10.1016/j.jcis.2024.12.174

Abstract

Dry eye disease (DED), a prevalent ocular disorder, affects nearly half the global population, bringing enormous health and economic burden. Currently, the predominant treatments for DED involve the administration of artificial tears, which is often hindered by continuous administration and constant reactive oxygen species (ROS) stimulus. Therefore, hyaluronan (HA)-modified cerium oxide (CeO₂) nanoparticles, HA-CeO₂, were developed to achieve simultaneous ROS scavenging and enhanced tear film stability. HA-CeO₂ was demonstrated to effectively scavenge ROS while concurrently downregulating the expression of inflammatory factors, such as MMP9 and IL-1β. Moreover, the anti-oxidative and anti-inflammatory effects of HA-CeO₂ were further confirmed through a DED mouse model. In addition, the biocompatibility and safety of HA-CeO₂ make it a promising treatment option for DED associated with inflammation and oxidative stress, offering novel insights into utilizing nanozymes in treating inflammation-oxidative stress-related diseases.

Keywords: Dry eye disease; Hyaluronan; Nanoceria; Nanozyme; Reactive oxygen species.